Back to:
Hospital doctors

Key contacts

Team inbox: srg2024review@nhs.scot

Sarah Wink, Project Manager sarah.wink2@gjnh.scot.nhs.uk

Jenny Johnston, Programme Manager jenny.johnston@nhs.scot

Accessibility checks

Content has been checked for accessibility in line with the relevant RDS standard operating procedure.

Governance

The Earlier Cancer Diagnosis Programme Board is the national cancer group responsible for SRGs.

Content management and review

The SRGs will be reviewed every 3 years although they may be subject to update before this period should new clinical evidence emerge. 

The Scottish Primary Care Cancer Group will flag any updates required based on emerging evidence. If any updates are identified, in between formal review cycles, this will then be taken to the Earlier Cancer Diagnosis Programme Board and any relevant cancer-specific clinicians engaged to ensure consensus (via SDGs, CfSD’s Primary and Secondary Care Interface Group (PCSCI) and/or Regional Cancer Networks).

Copyright

All content has been checked for copyright compliance.

Icons are sourced from Flaticon.com, accessed through the licence held by Tactuum Ltd as software provider of the RDS platform. 

Evidence base

CfSD commissioned Healthcare Improvement Scotland (HIS) and Cancer Research UK (CRUK) to undertake a review of current international cancer referral guidelines and emerging evidence for each tumour group. Relevant demographic data was also obtained from Scottish Government and Public Health Scotland (PHS).

Content was developed with extensive clinical engagement and is based on clinical consensus and current evidence.

Feedback and complaints

Emails for app enquiries or feedback are available in the "Key contacts" section above.

Messages received through the RDS Feedback form will be forwarded by the RDS team to the key contacts and team mailbox.

Feedback and complaints will be discussed by the SRG national project team, groups such as the SPCCG and PCSCI group will be involved as needed.

Risk assessment

The content has been risk assessed:

  • The toolkit does not reference medicines.
  • No risks to the safety of patients or service users have been identified.

User testing

User acceptance testing was carried out from 29/05/25 - 06/06/25 and 11/06/2025 - 24/06/2025.